Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
8.43
-0.84 (-9.06%)
Jun 5, 2026, 3:10 PM EDT - Market open
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
617.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCADL News
- 1 day ago - Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 days ago - Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene - TheFly
- 3 days ago - Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - GlobeNewsWire
- 3 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 17 days ago - Candel Therapeutics price target raised to $9 from $7 at BofA - TheFly
- 20 days ago - Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting - GlobeNewsWire
- 21 days ago - Candel Therapeutics Transcript: Study result - Transcripts